Perception of risk and treatment decisions in the management of differentiated thyroid cancer. Issue 2 (22nd March 2022)

• Record Type: Journal Article
• Authors: Schumm, Max A.; Shu, Michelle L.; Kim, Jiyoon; Tseng, Chi‐Hong; Zanocco, Kyle; Livhits, Masha J.; Leung, Angela M.; Yeh, Michael W.; Sacks, Greg D.; Wu, James X.
• Is Part Of: Journal of surgical oncology. Volume 126:Issue 2(2022)
• Page Start: 247
• Page End: 256
• Publication Date: 2022-03-22
• Subjects: behavioral science -- decision‐making -- risk and benefit -- thyroid cancer -- thyroidectomy -- thyroid surgery; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.26858
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Background and Objectives: The recent de‐escalation of care for differentiated thyroid cancer (DTC) has broadened the range of initial treatment options. We examined the association between physicians' perception of risk and their management of DTC. Methods: Thyroid specialists were surveyed with four clinical vignettes: (1) indeterminate nodule (2) tall cell variant papillary thyroid cancer (PTC), (3) papillary thyroid microcarcinoma (mPTC), and (4) classic PTC. Participants judged the operative risks and likelihood of structural cancer recurrence associated with more versus less aggressive treatments. A logistic mixed effect model was used to predict treatment choice. Results: Among 183 respondents (13.4% response rate), 44% were surgical and 56% medical thyroid specialists. Risk estimates and treatment recommendation varied markedly in each case. Respondents' estimated risk of 10‐year cancer recurrence after lobectomy for a 2.0‐cm PTC ranged from 1% to 53% (interquartile range [IQR]: 3%–12%), with 66% recommending lobectomy and 34% total thyroidectomy. Respondents' estimated 5‐year risk of metastastic disease during active surveillance of an 0.8‐cm mPTC ranged from 0% to 95% (IQR: 4%–15%), with 36% choosing active surveillance. Overall, differences in perceived risk reduction explained 10.3% of the observed variance in decision‐making. Conclusions: Most of the variation in thyroid cancer treatment aggressiveness is unrelated to perceived risk of cancer recurrence.